February 27, 2014 / 11:20 AM / 4 years ago

Valeant Pharmaceuticals swings to profit

Feb 27 (Reuters) - Valeant Pharmaceuticals International Inc , Canada’s largest listed drugmaker, reported a quarterly profit compared with a year-earlier loss, mainly driven by its acquisition of contact lens maker Bausch+ Lomb Holdings Inc.

Valeant posted net income attributable to the company of $123.8 million, or 36 cents per share, for the fourth quarter ended Dec. 31, compared with a loss of $89.1 million, or 29 cents per share, a year earlier.

Cash earnings, or profit adjusted for one-time items, was $732 million, or $2.15 per share.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below